Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RRM1 and ERCC1-directed customized chemotherapy versus standard gemcitabine + carboplatin in first-line advanced NSCLC
2008-000617-30Phase 3Active
- Sponsor
- Klinik Löwenstein
- Start
- Sep 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, vinorelbine, gemcitabine and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Klinik Löwenstein. Primary endpoint: Progression-free survival. Started Sep 2008; status: active.
02
Drugs
docetaxelvinorelbinegemcitabinecarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-000617-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000617-30.